Business · 1 sources covering this

I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend

AbbVie is entering a new chapter of growth, fueled by its blockbuster immunology drugs and expanding neuroscience business. Investor Kevin Simpson shares why he's optimistic.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·3h ago
I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend
AbbVie is entering a new chapter of growth, fueled by its blockbuster immunology drugs and expanding neuroscience business. Investor Kevin Simpson shares why he's optimistic.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/d8634c5a96bae2060e51c31b948982a5f94d8cd5"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend"></iframe>

I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend

How 1 sources are covering this

I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend

More from Business

Stocks making the biggest moves after hours: Visa, Robinhood, NXP, Seagate and more

Amex Platinum and Business Platinum add Airbnb perks, but lodging credit rules are tightening

Walmart says AI training is boosting confidence with the technology among its 2.1 million associates

CNBC Workforce Executive Summit live updates: How AI is reshaping work and jobs

Reader

Trust & legal

Across the network